New cocktail targets lung cancer brain metastases
NCT ID NCT06822543
First seen Oct 31, 2025 · Last updated Jun 23, 2026 · Updated 34 times
Summary
This phase 2 trial is testing a combination of three drugs—datopotamab deruxtecan, carboplatin, and pembrolizumab—in 46 people with non-small cell lung cancer that has spread to the brain and who have not had prior treatment for those brain tumors. The goal is to see how well the drugs shrink brain tumors. After four cycles, patients continue on two of the drugs until the disease gets worse or side effects become too severe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
FUNFARME - Hospital de Base de São José do Rio Preto
RECRUITINGSão José do Rio Preto, São Paulo, 15.090-000, Brazil
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
datopotamab deruxtecan, carboplatin, and pembrolizumab
What this could lead to
If successful, this combination could offer a new treatment option for lung cancer patients with brain metastases, potentially shrinking brain tumors and controlling the disease longer.
What could go wrong
This is a small, early-phase trial (46 people) with no control group, so results may not apply broadly. The drug combination can cause serious side effects, and it's unclear if it will work better than existing treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.